Statistics
Publications
2
Citations
36
H-Index
2
Active since
2022
Xiuxiu Xu is an author at Peking Union Medical College Hospital specializing in programmed death-ligand 1 inhibitors, cancer immunology, and checkpoint inhibitor therapy.
Publications per year
2022–2023
2
2
Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
Hui Tang, Ruixuan Geng, Xiuxiu Xu et al. · Frontiers in Immunology · 2022 · 13 citations · Full text
Life Sciences, Immunology, Oncology +17
1–2 of 2